We are international
Donate
TEXT SIZE   


Phase II VELCADE® Clinical Trials
05.01.08

US TRIALS

  • Phase II dose-response study of VELCADE and bone formation in patients with relapsed/refractory multiple myeloma (X05168)
    Little Rock, AR

  • UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE (2006-32)
    Little Rock, AR

  • A Phase II Pilot Study of the combination of (MEL-VTD) (2007-01)
    Little Rock, AR

  • Phase II trial of cyclophosphamide, bortezomib, and dexamethasone in newly diagnosed symptomatic multiple myeloma (X05210)
    Scottsdale, AZ

  • Phase II Study of Cyclophosphamide, Bortezomib, and Dexamethasone in patients with newly diagnosed active multiple myeloma (MAYO-MC0686)
    Scottsdale, AZ - multicenter

  • Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants (MCC-14184)
    Tampa, FL

  • A combination high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplant with bortezomib: a dose and schedule finding study (i063-341-03)
    Atlanta, GA

  • Phase II study to evaluate efficacy and safety of VELCADE plus dexamethasone administration of bortezomib in newly diagnosed multiple myeloma (X05153)
    Boston, MA - multicenter

  • Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (06-147)
    Boston, MA - multicenter

  • Phase II Study of Bortezomib, Melphalan, and Dexamethasone in Patients With Primary Systemic Amyloidosis or Light Chain Deposition Disease (WSU-2006-132)
    Detroit, MI

  • Phase II trial of twice weekly induction followed by once weekly IV VELCADE (bortezomib) with dexamethasone in patients with relapsed and/or refractory multiple myeloma following at least one prior therapy(i071-341-03)
    Lansing, MI- multicenter

  • Phase II Study of Induction Therapy and Maintenance Therapy Comprising Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (SPARROW-I071-341-03)
    Lansing, MI

  • A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (AV3502s)
    Hackensack, NJ

  • Phase II Study of VDT (VELCADE, Doxil, and thalidomide) as frontline therapy for patients with previously untreated multiple myeloma (MM) (X05144)
    Buffalo, NY

  • Phase II Pilot Study of Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as Front-Line Therapy in Patients With Previously Untreated Stage I, II, or III Multiple Myeloma (RPCI-I-59105)
    Buffalo, NY

  • Phase II clinical trial of bortezomib+liposomal doxorubicin+dexamethasone followed by thalidomide+dexamethasone or bortezomib+thalidomide+dexamethasone for patients with symptomatic untreated high-risk or primary resistant multiple myeloma (X05166)
    New York, NY

  • Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma (0504007841)
    New York, NY

  • A sequential phase II trial of the combination of bortezomib (VELCADE), dexamethasone (DECADRON) and pegylated liposomal doxorubicin (DOXIL) followed by high dose cyclophosphamide in multiple myeloma patients (X05178)
    New York, NY

  • Phase II Study of Bortezomib, Pegylated Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Patients With Symptomatic High-Risk or Primary Resistant Multiple Myeloma (MSKCC-06067)
    New York, NY

  • Phase II Study of Melphalan and Autologous Stem Cell Transplantation Followed By Adjuvant Bortezomib and Dexamethasone in Patients With Previously Untreated Systemic Light Chain Amyloidosis (MSKCC-07006)
    New York, NY

  • An Investigational Drug, PD 0332991, is Being Studied in Combination With Velcade and Dexamethasone in Patients With Multiple Myeloma (Must Have Received Prior Treatment for Multiple Myeloma) (A5481004)
    New York

  • Phase II study of an alternative schedule of VELCADE/dexamethasone in the treatment of multiple myeloma (X05203)
    Memphis, TN - multicenter

  • Bortezomib (Velcade) Post Allo for Myeloma (2003-0751)
    Houston, TX

  • Phase II Study of Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma (FHCRC-2123.00)
    Seattle, WA - multicenter

  • Phase II study of bortezomib (VELCADE) and doxorubicin in relapsed or refractory multiple myeloma (VEL-03-081)
    Madison, WI - multicenter

  • Ph 2 Bortezomib + Doxorubicin for Previously Treated Multiple Myeloma (HO04402)
    Madison, WI

  • Alternative Schedule of Velcade/Dexamethasone for Patients With Multiple Myeloma (ACORN ALJBMM0502)
    multicenter

  • A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma (CR012784)
    multicenter

  • A Comparative Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) to Treat Newly Diagnosed Patients With Multiple Myeloma Who Are Candidated for High-Dose Therapy and Stem Cell Transplantation (26866138-MMY-2043)
    multicenter

FOREIGN TRIALS

  • Bortezomib-Dexamethasone-Doxorubicin-Study (Eudract Number: 2005-003001-85)
    Vienna, Austria - multicenter

  • Phase II trial of bortezomib in combination with dexamethasone for relapsed multiple myeloma (VEL-AP-0094)
    East Melbourne, Australia

  • Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse (05/69)
    Melbourne, Australia

  • A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients (CR10927)
    Canada - multicenter

  • Combination Bortezomib-Containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma (26866138-MMY-2016)
    Toronto, Canada

  • Phase II Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Active Multiple Myeloma (MAYO-MC0686)
    Toronto, Canada - multicenter

  • Phase II study of bortezomib/dexamethasone and high-dose melphalan in patients relapsing after high-dose melphalan and autologous stem cell transplant (2006-VEL-EU-0030)
    Copenhagen, Denmark - multicenter

  • The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) (2006/175)
    Vejle, Denmark

  • Treatment of multiple myeloma (MM) for patients aged inferior or equal to 65 years, achieving a response superior or equal to 50% and inferior or equal to 90% after an autologous hematopoietic stem cell (HSC) transplantation by a gene-identical or phenotype (VEL-FRA-2005-07)
    Lyon, France - multicenter

  • Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% and <= 90% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (2005.385)
    Lyon, France

  • Phase II study to assess the safety, efficacy, and tolerability ofcombination therapy with VELCADE (bortezomib), adriamycin, and dexamethasone (PAD) as therapy for patients with relapsed or refractory multiple myeloma (VEL-EU-0061)
    Belfast, Ireland - multicenter

  • This Study Plans to Assess the Response of PAD Treatment to VAD or VAD-Like Treatment in Patients Who Have Relapsed or Refractory Myeloma (ICORG 05-01 PAD)
    Belfast, Ireland - multicenter

  • Bortezomib treatment before donor lymphocyte infusions (DLI) for myeloma patients relapsing or progressing after allogeneic transplantation of hematopoietic cells (alloHSCT) (X05156)
    Milano, Italy - multicenter

  • High-dose treatment of previously untreated multiple myeloma patients aged <65 years (VEL-EU-0075)
    Pavia, Italy

  • A multi-center, open label study of bortezomib, thalidomide and dexamethasone as consolidation therapy in newly diagnosed multiple myeloma patients who show at least a very good partial remission after autologous transplantation (VEL-03-096)
    Torino, Italy - multicenter

  • Phase II trial evaluating the safety and efficacy of VELCADE as maintenance treatment in patients with multiple myeloma following high dose melphalan treatment and autologous PBSCT in patients with minimal residual disease, patients in partial remission or with stable disease (i059-341-03)
    Tubingen, Germany - multicenter

  • VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) (DSMM VIII)
    Würzberg, Germany - multicenter

  • PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma (KMM55)
    Incheon, South Korea

  • VTD followed by MPT maintenance as a first line treatment for the patients with MM who are non-transplant candidates (KMM52)
    Incheon, South Korea

  • Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM (KMM51)
    Seoul, South Korea

  • A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma (CR012784)
    multicenter

  • Bortezomib Retreatment in Multiple Myeloma (CR010519)
    multicenter

  • Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma (CR011065)
    multicenter

  • Bortezomib and High-Dose Melphalan at Myeloma Relapse (NMSG 16-07)
    multicenter


 related articles